Andere talen Daré Bioscience, Inc.

Aandelen

DARE

US23666P2002

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 16-01-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,930 ^USD	-1,03%		-2,53%	-

10/12	DARE to PLAY? Sildenafilcrème nu beschikbaar voor pre-order op voorschrift: Eerste evidence-based topische opwindingscrème voor vrouwen start commerciële uitrol in geselecteerde staten via 503B outsourcingfaciliteit	CI
01/12	Dare Bioscience kondigt teruggave van rechten op Ovaprene aan; fase 3-programma loopt door met positieve tussentijdse data	RE

Andere talen

10/12	DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
10/12	DARE to PLAY? Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
01/12	Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data
01/12	Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
01/12	Dare Bioscience, Inc. Announces Return of Rights to Ovaprene; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
25/11	Dare Bioscience Receives $3.6 Million in Additional Grant Funding
24/11	Daré Bioscience Receives $3.6 Million in Additional Grant Funding
13/11	Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
13/11	Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11	Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream, November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health
11/11	Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health
06/11	Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
03/11	Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
03/11	Dare Bioscience to Receive Up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
06-10-25	Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
24-09-25	Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
14-08-25	Daré Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
14-08-25	Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07-08-25	Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
29-07-25	Dare Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support Dare to Play?? Sildenafil Cream
29-07-25	Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
21-07-25	Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
14-07-25	Top Midday Gainers
14-07-25	Daré Bioscience, Inc. Announces Positive Interim Safety and Efficacy Results from its Ongoing Phase 3 Clinical Trial Evaluating the Contraceptive
14-07-25	Dare Bioscience Announces Positive Results From Hormone-Free Contraceptive Trial; Shares Surge

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen MarketScreener-artikels MarketScreener-analyses Ideeën voor de handel

Andere talen Daré Bioscience, Inc.

Aandelen

DARE

US23666P2002

Farmaceutische producten

Andere talen

Filters